Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTL38 Fluorescence in RCC Surgery
NCT02645409Phase 2Completed
- Start
- Dec 2015
- Primary completion
- Mar 2018
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of pafolacianine in renal cell carcinoma (RCC) (2 arms). Primary endpoint: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens. Started Dec 2015; status: completed.
02
Drugs
pafolacianine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02645409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02645409.